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Type 3 diabetes is a new characterization of Alzheimer disease. The purpose of this comparative 
analysis is to outline and juxtapose Type 1 and Type 2 diabetes mellitus and Type 3 diabetes. 
This comparative analysis is based on published literature regarding both Type 1 and Type 2 
diabetes mellitus, as well as literature on glucose metabolism and regulation, in addition to the 
literature on Type 3 diabetes and Alzheimer disease. This analysis includes a brief description 
and introduction to the history of diabetes, along with molecular descriptions and demonstrations 
of glucose metabolism and regulation. The regulation of gene expression, signaling, and 
mechanisms of action were investigated and demonstrated for both insulin and glucagon. Type 1 
diabetes mellitus and Type 2 were discussed to the extent of manifestation of symptoms, 
molecular basis of the disease and pathophysiology of each type. Type 3 diabetes is also 
presented, including the molecular basis of the disease and the pathophysiology. Molecular 
mechanisms were compared and analyzed between both Type 1 and Type 2 diabetes mellitus and 
Type 3 diabetes. This paper reviews the evidence supporting the hypothesis that one form of 
Type 3 diabetes is related to Alzheimer disease, based on the molecular and clinical similarities 
between the mechanisms of vascular damage, insulin resistance, and formation of amyloid 





One could argue that diabetes is one of the most important diseases of our time. There is 
currently a pandemic-level problem that we have never faced before in human history. With the 
industrialization of food production as well as the continued rise in ‘fast food,’ we find ourselves 
with a record number of incidences for diabetes. It has become as important as ever to have a 
working knowledge of this disease given the ubiquity of it. Type 3 diabetes may be one of the 
newest scientific phenomena to be described, but it is still rooted in its ‘ancient’ predecessors, 
Type 1 and 2 diabetes. In order to understand the data giving rise to the hypothesis that Type 3 
diabetes is related to Alzheimer disease, it is important to have a working knowledge of both 
Type 1 and Type 2 diabetes mellitus, along with the molecular basis of these diseases.  
 
History of Diabetes 
 
The first reference to diabetes is in the Ebers Papyrus1: the famous papyrus acquired by 
the German Egyptologist Georg Ebers in 1872. Egyptian physicians were the first to treat and 
more importantly write about diabetes. In this document, written around 1550 BCE (with 
evidence that parts of it are much older), diabetes mellitus is detailed for the first time in human 
history. In particular, the Ebers Papyrus describes treatments for polyuria or to “eliminate urine 
which is too plentiful.”2 Other ancient characterizations of diabetes include the Ayurveda system 
of medicine in ancient India in the 5/6th Century BCE3, as well as in Ancient Chinese medicine 
                                                          
1 “Papyros Ebers: Das Hermetische Buch Über Die Arzneimittel Der Alten Ägypter in Hieratischer Schrift (Band 1): 
Einleitung Und Text.”. 
2 Sanders, Lee J. “From Thebes to Toronto and the 21st Century: An Incredible Journey.” 
3 Lakhtakia R. “The history of diabetes mellitus.” 
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around 475 BCE4. The Hindu physicians Charaka and Susruta were the first to use the term 
“honey urine” by noticing the “attraction of flies and ants to the urine.”2 
As we get closer to the contemporary understanding of diabetes, Aretaeus, a disciple of 
Hippocrates, represented the Ancient Greek view of the disease. Not only is he responsible for 
the term ‘diabetes,’ he also described the disease: “Diabetes is a wonderful affection, not very 
frequent among men, being a melting down of the flesh and limbs into urine…”5 This 
characterization is a bit on the dramatic side, but nonetheless, Aretaeus officially detailed the 
polyuria and polydipsia symptoms of diabetes in the first century.  
 Prior to the Renaissance, most of the developments for diabetes took place under Muslim 
physicians during the Islamic golden age, where the disease began to be further distinguished 
from other diseases with similar symptoms (polyuria)6. However, no real revolutionary change in 
the characterization of the disease occurred until the 19th Century. Within a hundred years the 
disease was linked to the pancreas by Thomas Crawley7 in Britain, as well as the much 
anticipated differentiation of diabetes insipidus and diabetes mellitus in the medical literature in 
17928. Past this point, diabetes and the study of its treatments started appearing at a rapid rate 
along the timeline and as such, a detailed description of every event far exceeds the scope of this 
paper. Diabetes is an ancient disease, and the timeline of it is fascinating, however to fully grasp 
the disease, the basis of normal glucose regulation in the body must be understood first. 
                                                          
4 Zhang, Hui, et al. “Study on the History of Traditional Chinese Medicine to Treat Diabetes.”  
5 Henschen, Folke. “On the Term Diabetes in the Works of Aretaeus and Galen: Medical History.” 
6 Eknoyan, Garabed, and Judit Nagy. “A History of Diabetes Mellitus or How a Disease of the Kidneys Evolved into 
a Kidney Disease.” 
7 Cawley, Thomas. “A Singular Case of Diabetes, Consisting Entirely in the Quality of the Urine; with an Inquiry 
into the Different Theories of That Disease.” 
8 Lindholm, Jörgen. “Diabetes Insipidus: Historical Aspects.” 
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Glucose Regulation  
To understand the mechanism of both Type 1 and Type 2 diabetes mellitus, it is first 
important to understand how the body functions normally in terms of glucose regulation. The 
two main hormones that participate in glucose metabolism are glucagon and insulin. Glucagon is 
a peptide hormone that is secreted by pancreatic alpha cells as well as intestinal L Cells9. 
Glucagon release and production is encoded by the pro-glucagon gene. This gene shown in 
Figure 1, contains 5 DNA response elements (G1-G5) as well as a cyclic-AMP-Response 
element (CRE)10. The regulation of this gene’s expression includes various transcription factors, 
one of the more relevant being Pax6. 
Figure 1: Schematic diagram of the glucagon gene promoter (rat) regulating expression in α‐
cells. (From: Diagram of the glucagon gene promoter. Adapted [reprinted] from Gosmain, Y., et 
al. “Glucagon Gene Expression in the Endocrine Pancreas: the Role of the Transcription Factor 
Pax6 in α‐Cell Differentiation, Glucagon Biosynthesis and Secretion.”) 
 
 
                                                          
9 Habegger, Kirk M, et al. “The Metabolic Actions of Glucagon Revisited.” 
10 Gosmain, Y., et al. “Glucagon Gene Expression in the Endocrine Pancreas: the Role of the Transcription Factor 
Pax6 in α‐Cell Differentiation, Glucagon Biosynthesis and Secretion.”  
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Pax6, is a transcriptional regulator of glucagon secretion. Although there are many factors that 
regulate transcription of this gene, Pax6 gives us a general idea on how this gene is regulated. A 
study out of the University of Geneva Medical School in 201211 showed how critical Pax6 is to 
glucagon expression. This study utilized “rat primary enriched-α cells with specific small 
interfering RNA leading to a 70% knockdown of Pax6 expression12” to demonstrate the 
importance of Pax6. Using glucagon secretion assays, they were able to show in these rat model 
α cells that there was a 42% decrease13 in relative glucagon levels in the partial Pax6 knockout 
models (see Figure 2C). These data were interpreted to show that in the absence of Pax6, 
glucagon secretion decreased significantly. This mechanism has also been shown to be 
applicable to human models for the same transcription factors, in terms of glucagon 
concentrations.14 While this is only a ‘surface-level’ analysis of this extremely complicated 







                                                          
11 Yvan Gosmain, Claire Cheyssac, Mounia Heddad Masson, Audrey Guérardel, Caroline Poisson, Jacques Philippe, 
“Pax6 Is a Key Component of Regulated Glucagon Secretion.” 
12 Yvan Gosmain, Claire Cheyssac, Mounia Heddad Masson, Audrey Guérardel, Caroline Poisson, Jacques Philippe, 
“Pax6 Is a Key Component of Regulated Glucagon Secretion.” 
13 Yvan Gosmain, Claire Cheyssac, Mounia Heddad Masson, Audrey Guérardel, Caroline Poisson, Jacques Philippe, 
“Pax6 Is a Key Component of Regulated Glucagon Secretion.” 
14 Ahlqvist, E., et al. “A Common Variant Upstream of the PAX6 Gene Influences Islet Function in Man.”  
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Figure 2: Representation of the effect of Pax6 gene silencing on glucagon synthesis and release. 
(From: Glucagon content relative to total protein amounts. Adapted [reprinted] from Yvan 
Gosmain, Claire Cheyssac, Mounia Heddad Masson, Audrey Guérardel, Caroline Poisson, 
Jacques Philippe, “Pax6 Is a Key Component of Regulated Glucagon Secretion.”) 
 
 
 Glucagon signaling takes place via a specific seven transmembrane G protein-coupled 
receptor. This receptor is most prevalent in the tissues of the liver and pancreas given the role of 
both organs in blood glucose regulation. The activation of the glucagon receptor or GPCR is a 
typical representation of a G-protein signaling cascade. Once glucagon binds its receptor, it 
triggers a conformational change that activates the heterotrimeric G protein complex. 
Specifically, this conformational change allows the receptor to act as a guanine nucleotide 
exchange factor (GEF) and exchange GDP for GTP on the α subunit of the complex. This 
transfer activates the complex and cause the dissociation of the α subunit (αGTP) from the β and 
γ subunit as well as the receptor itself. The activated Gα subunit then activates adenylyl cyclase 
(AC), an effector enzyme, which produces cyclic adenosine monophosphate (cAMP) from ATP. 
cAMP is an extremely important intracellular signaling transductor and involved in many 
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signaling cascades. For glucagon secretion, there is evidence that modulation of cAMP levels 
can influence secretion independent of any paracrine signaling15. After its synthesis, cAMP then 
binds to Protein Kinase A (PKA) activating it and allowing for PKA to phosphorylate the 
enzyme phosphorylase kinase (PPK) (Figure 3). This enzyme then phosphorylates glycogen 
phosphorylase (PYG) which is the enzyme that breaks down glycogen to yield glucose-1-
phosphate16. PKA also phosphorylates the glycogen synthase enzyme (GYS), inactivating it. 
Under normal conditions, glycogen synthase is the enzyme that synthesizes glycogen from 
glucose-1-phosphate.  
Figure 3:  Schematic of glucagon mechanism of action. (From: Pathway of glucagon action. 
Adapted [reprinted] from Man, Frozen. “Image/PNG.”) 
 
 
                                                          
15 Yu, Qian, et al. “Glucose Controls Glucagon Secretion by Directly Modulating CAMP in Alpha Cells.”  
16 Berg, Jeremy M. “Phosphorylase Is Regulated by Allosteric Interactions and Reversible Phosphorylation.”.  
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This signaling cascade can also act on glucagon in terms of promoting gene expression. 
Activated PKA acts to phosphorylate/activate, as well as localize to the nucleus, molecules like 
CREB (cAMP response element-binding protein) (Figure 4). CREB can independently promote 
expression of the glucagon gene. However, through the effector IP3 (inositol 1,4,5-triphosphate), 
which enhances calcium release, other downstream signaling effectors can be activated like 
CRTC2 (Figure 4). CRTC2 is a transcriptional co-activator for CREB and acts to enhance 
overall gene expression.17 Consequently, there is a positive feedback loop where an increase in 
glucagon-mediated signaling pathways results in increased expression of the glucagon gene. 
Figure 4: Schematic representation of glucagon signaling cascade. (From: Glucagon Signaling 
cascade. Adapted [reprinted] from Rix, Iben. “Glucagon Physiology.”) 
 
 
                                                          
17 Rix, Iben. “Glucagon Physiology.” 
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The main action of glucagon is the raising of the concentration of blood glucose. The hormone 
accomplishes this goal through two processes, gluconeogenesis and glycogenolysis. 
Glycogenolysis, or the breakdown the glycogen is accomplished by the glycogen phosphorylase 
enzyme, which as previously stated, breaks down glycogen to yield glucose-1-phosphate. 
Gluconeogenesis is the metabolic pathway in which glucose is formed de novo. This pathway 
(shown below) (Figure 5) consists of 11 steps starting with pyruvate and ending with glucose. 
One of the most important steps in this reaction is the last step, the conversion of glucose-6-
phosphate into glucose. This reaction occurs via the hydrolysis action of glucose-6-phosphatase, 
a membrane bound enzyme. For glucose to diffuse out of the cell, it must lose the attached 
phosphate. This is an important decision point for the cell, as leaving the phosphate on glucose 
relegates it to the inside of the cell where it can be used in the formation of glycogen. 
Consequently, the enzyme glucose-6-phosphatase is mainly found in tissues where maintenance 










Figure 5: Gluconeogenesis pathway. Four enzymes in red are used in the gluconeogenesis 
pathway, along with other enzymes in blue also used in glycolysis. (From: Gluconeogenesis 





Glucagon secretion is a tightly regulated process with glucagon secretion being 
influenced by several different molecules (Figure 6). Obviously, low blood glucose levels are 
the most direct positive regulators on glucagon secretion. When blood sugar is low, 
hypoglycemia, glucagon secretion is stimulated and under hyperglycemic conditions, glucagon 
secretion is inhibited. In the past, the predominant model proposed that glucagon secretion was 
in response directly to the variation in blood glucose levels. At present, the thought is that the 
regulation of glucagon is not only influenced by fluctuating blood glucose levels, but also by 
various paracrine/autocrine/endocrine molecules.18  
Figure 6: Diagram of glucagon regulation, including negative and positive regulators. (From: 
Factors that regulate glucagon secretion, as well as the action of glucagon. Adapted [reprinted] 
from Kate, Nilesh. “PDF.”) 
 
 
                                                          
18 Jesper Gromada, Isobel Franklin, Claes B. Wollheim, α-Cells of the Endocrine Pancreas: “35 Years of Research 
but the Enigma Remains.” 
 13 
Glucagon is positively regulated by an increase in amino acids as well as an increase in 
parasympathetic and sympathetic nerve activity. An increase in amino acids usually parallels a 
decrease in blood glucose, usually indicating a need for nutritional energy. The autonomic 
nervous system also plays a role in the regulation of glucagon, especially the neurotransmitter 
epinephrine. Glucose is incredibly important in terms of brain activity, so when declining blood 
glucose levels are sensed, epinephrine (in addition to glucagon) is released. Functionally, 
epinephrine acts like a coactivator of the glycogenolysis process. In the liver, epinephrine can 
bind its α2-adrenergic receptor, along with its β2-adrenergic receptor19. This binding triggers a 
signaling cascade called the phosphoinositide cascade. Through the effector phospholipase C, 
inositol 1,4,5-trisphosphate is produced, promoting the release of Ca2+ from the ER20. 
Phosphorylase kinase is the enzyme that phosphorylates glycogen phosphorylase, the enzyme 
that breaks down glycogen to yield glucose-1-phosphate. The δ subunit of this enzyme is 
calmodulin21, which senses the increase Ca2+ levels, thus partially activating the enzyme. This 
increase in Ca2+ levels also assists in the exocytosis of glucagon22. Overall, glucagon secretion 
is regulated by a myriad of molecules, both positively and negatively. One of the most powerful 
negative regulators of glucagon secretion is insulin.  
Insulin is the other major hormone involved in glucose regulation. Insulin is a peptide 
hormone that is secreted by the pancreatic beta cells. Insulin production is encoded by the INS 
gene. Much like the glucagon gene, the INS gene is highly regulated for the production of 
                                                          
19 Brian T. Layden, M.D., Ph.D., Vivek Durai & William L. Lowe, Jr., M.D. “G-Protein-Coupled Receptors, 
Pancreatic Islets, and Diabetes.”  
20Berg, Jeremy M. “Epinephrine and Glucagon Signal the Need for Glycogen Breakdown.”  
21Kilimann, M W, et al. “The Alpha and Beta Subunits of Phosphorylase Kinase Are Homologous: CDNA Cloning 
and Primary Structure of the Beta Subunit.”    
22Gromada, J, et al. “Adrenaline Stimulates Glucagon Secretion in Pancreatic A-Cells by Increasing the Ca2 Current 
and the Number of Granules Close to the L-Type Ca2 Channels.”   
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insulin. The gene’s promoter comprises 3 main sites, A3, E1 and the C1 site (Figure 7). There 
are three main transcription factors acting on the promoter region of the gene, Pdx-1, MafA and 
NeuroD1. While the specific mechanism of action for these transcription factors remains 
unknown, in general they “act in a coordinated and synergistic manner to stimulate insulin gene 
expression in response to increased glucose levels.”23 Insulin, like most peptide hormones 
requires some post-translational modifications. Unlike other peptide hormones, the post-
translational modifications for insulin are clinically significant based on their products. Once the 
insulin gene begins to be expressed, preproinsulin is produced, and via its signal peptide is 
translocated to the ER. Once in the ER, the signal peptide is cleaved, creating proinsulin. 
Proinsulin folds and forms disulfide bonds and is then transported to the Golgi apparatus. To 
become active insulin, proinsulin gets cleaved by various endopeptidases, leaving the B and A 
chains disulfide-bonded together and releasing the C peptide fragment24. C peptide levels are 
clinically significant as a low C-peptide level means that the body is not producing enough 
insulin, a marker of diabetes mellitus. 
Figure 7: Schematic view of the promoter region of the INS gene encoding insulin. (From: 
Schematic of INS gene. Adapted [reprinted] from Sreenath S. Andrali, Megan L. Sampley, 




                                                          
23 Andrali, et al. “Glucose Regulation of Insulin Gene Expression in Pancreatic β-Cells.” 
24 Weiss, Michael. “Insulin Biosynthesis, Secretion, Structure, and Structure-Activity Relationships.”  
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Insulin release is a multi-step pathway that is critical to the regulation of plasma glucose 
levels. Glucose enters pancreatic beta cells through GLUT2 transporters, which are only present 
in beta cells as they have a much lower affinity for glucose relative to GLUT4 transporters, 
which are found in muscle and adipose cells. This low affinity of GLUT2 ensures that there must 
be a high enough glucose concentration to warrant insulin release. Once glucose enters the cell it 
is phosphorylated by glucokinase and proceeds to enter glycolysis to produce ATP. This increase 
in ATP levels coincides with a “closure of KATP channels, [a] depolarization of the plasma 
membrane, [and a] opening of voltage-dependent Ca2+ channels.”25 This increase in intracellular 
Ca2+ levels causes the release of insulin from its secretory vesicles (Figure 8).26 
Figure 8: Mechanism of insulin release and action within the cell. (From: Insulin release 
pathway and mechanism of action. Adapted [reprinted] from Fu, Zhuo, et al. “Regulation of 
Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes.”) 
 
                                                          
25 Fu, Zhuo, et al. “Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in 
Diabetes.”  
26 Fu, Zhuo, et al. “Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in 
Diabetes.” 
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Once insulin is released from its secretory vesicle, it is free to begin its own signaling 
cascade. Unlike glucagon, insulin signaling takes place via a single transmembrane receptor 
tyrosine kinase, or RTK. Upon insulin binding to the β subunit of the RTK, autophosphorylation 
occurs and begins the signaling cascade starting with insulin receptor substrates (IRS). There are 
two main signaling pathways for insulin, the PI3K pathway and the Ras-MAPK pathway. For the 
purposes of this review, the PI3K pathway will be discussed. Once the IRS are phosphorylated, 
they activate various kinases, in particular the phosphoinositol 3 kinase or PI3K. This enzyme 
then converts PIP2 (phosphatidylinositol 4,5-bisphosphate) to PIP3 (phosphatidylinositol 3,4,5-
triphosphate). PIP3 then binds to and activates protein kinase B (PKB) (also called AKT).27 Once 
PKB is activated, it promotes the fusion of GLUT4 glucose transporters within the cell 
membrane. GLUT4 transporters transport glucose into muscle and adipose tissues where the 
glucose is either converted into glycogen, or broken down by glycolysis to yield ATP. PKB also 
inactivates glycogen synthase kinase (GSK), which activates glycogen synthase, via 
phosphorylation.28 This inactivation means that GSK cannot deactivate the glycogen synthase 
enzyme and thus glycogen continues to be produced. The overall goal of the peptide hormone 
insulin is to reduce plasma glucose levels, by either producing glycogen or by producing ATP.  
Insulin production, like glucagon is tightly regulated, most directly by elevated plasma 
glucose levels. When blood sugar is low, hypoglycemia, insulin secretion is inhibited, as there is 
not enough glucose being transported through GLUT2 transporters to warrant a significant 
depolarization effect. Under hyperglycemic conditions, insulin secretion is stimulated via the 
action previously discussed. Other molecules that positively regulate insulin include 
                                                          
27 Meyts, Pierre De. “The Insulin Receptor and Its Signal Transduction Network.” 
28 Fang, X, et al. “Phosphorylation and Inactivation of Glycogen Synthase Kinase 3 by Protein Kinase A.”  
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acetylcholine. Acetylcholine positively regulates insulin via “moderate membrane depolarization 
and increased β-cell electrical activity.”29 Negative regulators of insulin release include 
somatostatin and epinephrine, which both exhibit “strong membrane repolarization and … 
inhibition of action potential firing.”30 
Both glucagon and insulin and glucagon work in harmony to regulate blood glucose 
levels in the body (Figure 9).31 The mechanisms required to maintain this harmony are 
complicated and thus can become disrupted in a multitude of ways to yield pathology. 
Figure 9: Diagram of the overall plasma glucose regulation mechanism in the body. (From: 
Diagram of plasma glucose regulation. Adapted [reprinted] from Jesper Gromada, Isobel 
Franklin, Claes B. Wollheim, “α-Cells of the Endocrine Pancreas: 35 Years of Research but the 
Enigma Remains.”) 
 
                                                          
29 Rorsman, Patrik, and Matthias Braun. “Regulation of Insulin Secretion in Human Pancreatic Islets.”  
30 Rorsman, Patrik, and Matthias Braun. “Regulation of Insulin Secretion in Human Pancreatic Islets.” 
31 Jesper Gromada, Isobel Franklin, Claes B. Wollheim, “α-Cells of the Endocrine Pancreas: 35 Years of Research 
but the Enigma Remains.” 
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Type 1 Diabetes Mellitus 
Type 1 diabetes mellitus was often referred to as juvenile diabetes, given that childhood 
was often when it was diagnosed.  However, as Type 1 diabetes is also diagnosed in adult 
patients, the name ‘juvenile diabetes’ has been abandoned by the medical community. Symptoms 
of Type 1 diabetes mellitus include “excessive excretion of urine (polyuria), thirst (polydipsia), 
constant hunger, weight loss, vision changes, and fatigue.”32 The unfortunate reality of Type 1 
diabetes is that the cause is still largely unknown, with genetics and environment being the 
predominant theories. However, be it genetics or environment, the pathophysiology of the 
disease is the same. Type 1 diabetes mellitus is an autoimmune disorder in which the beta cells 
of the pancreas are destroyed which results eventually in no insulin production. Specifically, an 
increase in autoreactive CD4+ and CD8+ T cells, along with an overall activation of the innate 
immune system, work together to destroy the pancreatic beta cells. In a normally functioning 
immune system, the system can distinguish between ‘self’ and ‘not self.’ However, in 
autoimmune disorders like Type 1 diabetes, these immune cells react to ‘self’ and seek to destroy 
pancreatic beta cells. Specifically these CD4+ and CD8+ T cells are activated in the pancreatic 
draining lymph nodes because of a “high turnover of β-cells in the islets leading to antigen 
presentation.”33 Once the T cells are ‘made aware’ of the pancreatic islets, a multiplication effect 
takes place, making the destruction even more wide spread and leading to the insulitis, an overall 
destruction of the beta cells (Figure 10).  
 
 
                                                          
32 “Diabetes.” World Health Organization 
33 Bluestone, Jeffrey A, et al. “Genetics, Pathogenesis and Clinical Interventions in Type 1 Diabetes.” 
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Figure 10: Process of destruction of pancreatic beta cells via autoimmune induced insulitis. 
(From: Mechanism of destruction of pancreatic beta cells via insulitis. Adapted [reprinted] from 
Bluestone, Jeffrey A, et al. “Genetics, Pathogenesis and Clinical Interventions in Type 1 
Diabetes.”) 
 
 One of the most indicative conditions associated with Type 1 diabetes is a condition 
called diabetic ketoacidosis (DKA). DKA is drastic example of the complications associated 
with Type 1 diabetes. DKA is characterized by an extremely high blood glucose level as a result 
of a lack of insulin action. As a result of a lack of insulin and a consequential lack of glucose 
transport into cells, the body begins to rely on other sources of energy. This includes the 
breakdown of fatty acids, a process called lipolysis. This breakdown of fats via beta oxidation 
yields ketone bodies (acetoacetate and β-hydroxybutyrate). These ketone bodies are partially 
acidic and begin to lower the plasma pH level. The body can initially compensate through the 
use of bicarbonate buffering, but eventually the system becomes overwhelmed and the body 
enters acidosis. To compensate, patients often exhibit Kussmaul breathing, which is 
hyperventilation in order to lower blood carbon dioxide levels34. DKA can eventually progress to 
                                                          
34Kitabchi, Abbas E., et al. “Hyperglycemic Crises in Adult Patients With Diabetes.” 
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cerebral edema and eventually death if left untreated. DKA is not unique to patients with Type 1 
diabetes, as patient with Type 2 diabetes can develop the condition as well, although it is 
significantly rarer. 
 
Type 2 Diabetes Mellitus 
The second type of diabetes mellitus is often referred to as ‘late-onset’ or ‘adulthood’ 
diabetes as it usually develops later in life. However, as this disease is also diagnosed in teens or 
younger children, the former names have been replaced with Type 2 diabetes. (There are also 
other rare types of diabetes mellitus that will not be discussed in this paper.) While Type 1 is 
characterized by a complete destruction of pancreatic beta cells and a complete lack of insulin 
production, Type 2 is characterized by ‘insulin resistance.’ Some of the symptoms of Type 2 
diabetes mellitus are the same as Type 1, including, “excessive excretion of urine (polyuria), 
thirst (polydipsia), constant hunger, weight loss, vision changes, and fatigue.”35 The main 
difference between the two is that the symptoms for Type 2 tend to come on slower and are less 
abrupt.36 The causes of Type 2 diabetes mellitus are much better characterized than those of 
Type 1. Type 2 can develop from long term diet issues/obesity along with contributing genetic 
factors. A meta-analysis done in 2010 looked at multiple studies on the disease and concluded 
that “the relative risk of developing Type 2 diabetes for obese persons, compared to those with 
normal weight was 7-fold, and the risk for overweight people was almost 3-fold.”37 A social 
                                                          
35 “Diabetes.” World Health Organization 
36 “Symptoms & Causes of Diabetes.” National Institute of Diabetes and Digestive and Kidney Diseases, U.S. 
Department of Health and Human Services. 
37 Abdullah, Asnawi, et al. “The Magnitude of Association between Overweight and Obesity and the Risk of 
Diabetes: A Meta-Analysis of Prospective Cohort Studies.” 
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perspective would also be helpful in looking at the cause of Type 2 diabetes. Simply put, the 
world today has seen an enormous rise in cheap, high calorie foods which are being consumed at 
a rapid rate. ‘Fast’ and low quality food is being utilized as a band-aid on social issues like 
poverty and hunger. Unfortunately, the result is the highest level of obesity in the history of the 
mankind. This has contributed to the almost meteoric rise in Type 2 diabetes. Looking past the 
social influences on Type 2 diabetes, genetics may also play a role.  
 Single nucleotide polymorphisms are the basis for some of the genetic contributions to 
the development of Type 2 diabetes. In 2010, at the Leibniz Center for Diabetes Research at 
Heinrich Heine University Düsseldorf, it was determined via GWAS (genome‐wide association 
studies) that “at least 36 gene loci have been identified that contribute to the genetic risk of type 
2 diabetes.”38 These genes vary in responsibility from encoding for islet ATP-sensitive 
potassium channels to transcription factors for the proglucagon gene.39  
 The pathophysiology of Type 2 diabetes begins with the notion of insulin resistance as 
well as dysfunction in pancreatic beta cells. In normal functioning pancreatic beta cells, glucose 
is transported into the cell via GLUT2, triggering the activation of glucokinase, and the release 
of insulin. However, in some patients with Type 2 diabetes, the action of glucokinase is severely 
reduced, not as a result of the efficacy of the enzyme itself, but rather because glucose transport 
is severely reduced.40 Type 2 diabetes is more of a generalized term that describes multiple 
different disease processes. All the mechanisms have in common the insulin resistance property, 
which is a disruption in the ‘second step’ of insulin action. If the body’s cells are not responding 
to insulin production as they normally should, then that is considered insulin resistance. Unlike 
                                                          
38 Roden, Michael. “Genetics of Type 2 Diabetes: Pathophysiologic and Clinical Relevance.” 
39 Rother, Kristina I. “Diabetes Treatment--Bridging the Divide.”  
40 Porte, D. “Banting Lecture 1990. Beta-Cells in Type II Diabetes Mellitus.” 
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Type 1, in Type 2 the beta cells of the pancreas are functioning properly and producing insulin; 
however, that insulin is not being recognized by cells in their normal capacity. This disruption 
can be caused by several things. Most patients with Type 2 diabetes struggle with either obesity, 
or a long-term poor diet. This can cause chronic hyperglycemia which consequentially causes 
long-term hyperinsulinemia. This long-term elevation of insulin inhibits its action as well as 
production through its own feedback system.41 Specifically, it is thought to inhibit insulin action 
through a process usually present before pathogenesis. The studies on non-diabetic relatives of 
patients with diabetes have been found to have “decreased stimulation of [the] tyrosine kinase 
activity of the insulin receptor.”42 Having elevated blood glucose levels long-term can also cause 
the development of a phenomenon called “glucose toxicity.” This is where chronic 
hyperglycemia begins to change the normal insulin response to glucose just based on over-
saturation,43 or more specifically by the “accumulation of glucose within the β-cell.”44 Similar to 
Type 1 diabetes, patients with Type 2 diabetes can also experience beta cell loss as a result of 
autoimmune activation. This makes up only about 10% of Type 2 diabetes cases in specific 




                                                          
41 DeFronzo, R A, et al. “Sensitivity of Insulin Secretion to Feedback Inhibition by Hyperinsulinemia.”  
42 Vaag, A, et al. “Decreased Insulin Activation of Glycogen Synthase in Skeletal Muscles in Young Nonobese 
Caucasian First-Degree Relatives of Patients with Non-Insulin-Dependent Diabetes Mellitus.” 
43 Yki-Järvinen, H. “Glucose Toxicity.” 
44 Richard J. Mahler, Michael L. Adler, “Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and 
Treatment.” 
45 Richard J. Mahler, Michael L. Adler, “Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and 
Treatment.” 
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Type 3 Diabetes 
 To put it simply, Type 3 diabetes does not present as Type 1 and Type 2 diabetes 
mellitus, at least not yet in the clinical sense. Type 3 diabetes is a characterization of insulin 
resistance in Alzheimer disease. Initially, the connection between traditional pancreatic diabetes 
and Alzheimer disease was not clear. Granted, the connection has only been theorized since 2008 
from researchers at Brown University.46 Alzheimer disease is a chronic neurodegenerative 
disorder and is the prevailing cause of dementia. The cause of Alzheimer disease has long 
escaped researchers, with the prevailing theories being that 70% of the risk of the disease is 
attributable to genetics,47 with head injuries and chronic hypertension following closely behind.48  
 The pathophysiology of Alzheimer disease is based on the misfolding of proteins in the 
brain, specifically the misfolding of amyloid β peptide (Aβ), which is a part of the larger amyloid 
precursor protein (APP). APP is a transmembrane protein in neurons. It functions in “adhesion, 
neurotrophic and neuroproliferative activity”49 along with intercellular communication. One of 
the theories on the pathology of Alzheimer disease is the “possibility that Aβ peptide and α-
synuclein might interact to cause mitochondrial and plasma membrane damage."50 This damage 
could trigger an apoptosis (cytochrome c) cascade which explains the overall neurodegenerative 
effect of the disease. Characterizations of Alzheimer disease lack any significant mechanism in 
                                                          
46 Editor. “Type 3 Diabetes Is a Title That Has Been Proposed for Alzheimers Disease Which Results from 
Resistance to Insulin in the Brain.” 
47 Ballard, Clive, et al. “Alzheimer's Disease.” 
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50 Hashimoto, Makoto, et al. “Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in 
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terms of what gives rise to the disease. The Type 3 diabetes characterization of Alzheimer 
disease may finally be suggesting a significant mechanism for the disease. 
 There are 3 main connections between Alzheimer disease and diabetes, the first of which 
being the vascular dementia connection. Chronic hyperglycemia in Type 2 diabetes can lead to 
oxidative stress via PKC activation.51 PKC or Protein kinase C, is a universal signaling molecule, 
and its upregulation in diabetes contributes to vascular damage via reactive oxygen species from 
the activation of the NOX1 Enzyme (Figure 11). These reactive oxygen species (ROS) 
contribute to the overall endothelial dysfunction. Overall, vascular damage can contribute to 
neurodegeneration via a “disruption of white matter networks.”52 
Figure 11: Mechanisms of NOX activation in hyperglycemic conditions. (From: Mechanism and 
pathway of NOX activation. Adapted [reprinted] from Meza, et al. “Endothelial Dysfunction: Is 
There a Hyperglycemia-Induced Imbalance of NOX and NOS?”) 
 
 
                                                          
51 Rask-Madsen, Christian, and George L King. “Vascular Complications of Diabetes: Mechanisms of Injury and 
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52 Cholerton, Brenna, et al. “Type 2 Diabetes, Cognition, and Dementia in Older Adults: Toward a Precision Health 
Approach.” 
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The next major connection between Alzheimer disease and diabetes is the formation of 
amyloid plaques. Much like in Alzheimer disease, there is formation of amyloid polypeptide, or 
plaques in Type 2 diabetes. Insulin is regulated by an islet amyloid polypeptide called amylin, 
also known as IAPP. IAPP is co-secreted with insulin and assists in the slowing of gastric 
motility, as well as promoting satiety.53 The specific mechanism for the increase in IAPP in Type 
2 diabetes patients is not yet known, however the predominant hypothesis is based on insulin 
resistance.54 As a result of pancreatic beta cell loss, there is a compensatory increase in insulin 
and IAPP secretion, and this compensatory increase is thought to lead to the accumulation of 
aggregated, oligomer IAPP proteins and extracellular plaques.55 The progression of Type 2 
diabetes generates an increase in apoptosis of pancreatic beta cells. In Alzheimer disease, the 
accumulation of the amyloid β peptides are thought to also initiate an increase in apoptosis in 
neurons. However, in Type 2 diabetes there is evidence to suggest that the toxic oligomer form 
of IAPP is more responsible for apoptosis than the extracellular amyloid plaques.56 The 
accumulation of IAPP in Type 2 diabetes, much like the accumulation of amyloid β peptides in 
Alzheimer disease and the resulting pathology of both mechanisms, gives rise to the strong 
connection between diabetes and Alzheimer disease. 
The last major connection between Alzheimer disease and diabetes is the insulin 
resistance in the brain connection. Although the effects of insulin binding the insulin receptor in 
so-called “insulin-dependent tissues,” such as muscle, adipose and liver tissues, are well 
understood, insulin binding a different insulin receptor in the brain is extremely important for 
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many neurological effects.  The major glucose transport mechanisms in the brain utilizing the 
GLUT-1 and GLUT-3 glucose transporters are independent of insulin. However, recent research 
has provided a glimpse into the role of insulin binding the insulin receptor in the brain and the 
effect on insulin-dependent glucose transport via GLUT-4.57 Glucose transport in the brain is 
paramount to achieve normal neuronal function. Past that, insulin also assists with neuronal 
growth as well as being involved in the regulation of synaptic plasticity and genes related to long 
term memory.58 As previously discussed, the mechanism for insulin resistance in Type 2 diabetes 
is essentially defective insulin signaling, or tissue cells not responding to insulin production as 
they normally should. The mechanism is similar for Alzheimer disease. The presence of 
misfolded amyloid β peptide (Aβ) in hippocampal neurons has been shown to be associated with 
insulin insensitivity.59 Specifically, the inhibition of IRS (Figure 12) has “major impact on 
synaptic dysfunction, impaired synaptic plasticity, and synapse loss.”60 After the activation of the 
insulin receptors, an autophosphorylation cascade occurs, with IRS1, Akt and GSK-3 molecules 
being phosphorylated by c-Jun N-terminal kinases (p-JNK). Insulin resistance decreases the 
effect of the p-JNK which reduces the overall effect of the signaling cascade. The decrease of p-
JNK causes the IRS1 that is phosphorylated at its serine residue to become favored over the 
normal tyrosine phosphorylation, inhibiting the IRS enzyme.61 The presence of insulin resistance 
in diabetes as well as Alzheimer disease further establishes a strong connection between the two 
diseases. 
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Figure 12: Molecular mechanism and pathway linking insulin resistance and Alzheimer disease. 
(From: Mechanism and Pathway of insulin resistance in Alzheimer disease. Adapted [reprinted] 
from Benedict, et al. “Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimers 




 Diabetes is an extremely complicated disease. Not only is the pathophysiology of 
diabetes mellitus multifaceted, the genetic basis is extremely intricate and not yet characterized. 
Looking past the science to the more social aspect of the disease, it is easy to get lost in a 
complicated structure of influences on not only the prevalence of the disease but the actual 
manifestation. With the sheer prevalence of diabetes in our world today, it is no surprise that the 
disease is beginning to find its way into other disease in terms of pathophysiology. Recent data is 
consistent with the connection between Type 3 diabetes and Alzheimer disease. Whether it be 
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through the common mechanism of insulin resistance, vascular damage, or through the formation 
of amyloid plaques, there is significant data that shows a connection. Not only that, but the risk 
for developing Alzheimer disease is 1.5-fold higher among patients with Type 2 diabetes.62 The 
one major difference between the two diseases is that there is a much clearer path to management 
and treatment for diabetes mellitus than there is for Alzheimer disease. Type 3 diabetes may be a 
new avenue for treating Alzheimer disease. In fact, intranasal insulin is already being used to 
treat the disease.63 While the literature does not (currently) think that Type 3 diabetes is a cause 
of Alzheimer disease, it is at the very least intimately involved in terms of pathology.  
 While researching Type 3 diabetes, the question had to be asked, did Type 3 arise purely 
out of a massive cultural presence of diabetes in general? Or has the rampant diabetes epidemic 
begun to influence our characterization of other diseases? While the characterization may have 
begun that way, the research that has been done since has provided much more validity to the 
argument. The avenue for treatment is undoubtedly the most exciting part of Type 3 diabetes. At 
least for now, there is a gap between the knowledge of a connection of diabetes and Alzheimer 
disease and a lack of an understanding of the mechanism of Alzheimer disease itself. But the 
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